Guideline on similar biological medicinal products ...
The Guideline on similar biological medicinal products containing biotechnology -derived proteins as active substance: quality issues lays down the quality requirements for a biological medicinal product claiming to be similar to another one already marketed.
Tags:
Product, Biological, Medicinal, Biotechnology, Containing, Derived, Similar, Similar biological medicinal, Biological medicinal, Similar biological medicinal products containing biotechnology derived
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Product, Management, Lifecycle, Product lifecycle management
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guidelines, Good, Practices, Clinical, Good clinical practice e6
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients
Related documents
Guideline on similar biological medicinal products ...
www.ema.europa.euGuideline on similar biological medicinal products containing biotechnology -derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/05 Rev.1) lays down the non-clinical and clinical requirements for a …
Biological, Medicinal, Similar, Similar biological medicinal
Isosteresin Medicinal Chemistry Group Meeting Christos ...
www.scripps.edubiological activity. Thornber(1979): Groups or molecules which have chemical and physical similarities producing broadly similar biological effects. Parameters affected with bioisostericreplacements Size, conformation, inductive and mesomericeffects, polarizability, H-bond formation capacity, pK a, solubility, hydrophobicity, reactivity, stability.
Biological, Chemistry, Group, Meeting, Medicinal, Similar, Isosteresin medicinal chemistry group meeting, Isosteresin, Similar biological
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ec.europa.euThis medicinal product is subject to additional monitoring. This will allow quick identification of ... In order to improve the traceability of biological medicinal products, the name and the batch number . ... baseline, was similar to that seen in the general population. Reporting of suspected adverse reactions .
PRINCIPLES OF MEDICINAL CHEMISTRY
www.ysmubooks.ambetween chemical structure and biological activity, theories of drug action, and mechanism of ... Definition Medicinal chemistry, also called therapeutic chemistry, pharmaceutical chemistry, pharmacochemistry, and chemical pharmacy is that field of pharmaceutical sciences which applies the ... more active, and c) with similar or different ...
Principles, Biological, Chemistry, Medicinal, Similar, Principles of medicinal chemistry
Recommendations for the evaluation of animal cell cultures ...
www.who.intHistorically, the major concerns regarding the safety of biological medicinal products manufactured in animal cells have been related to the possible presence of microbial contaminants and, in some cases, to the properties and components of the cells themselves such as DNA and proteins.
Transport route profiling qualification
www.who.intoverall size and weight should be similar to the container(s) used for the product(s) which are being monitored – this will ensure that the same handling practices are used. Warm life (test): The empty passive container is stabilized at +18.0°C and loaded with warm water-packs, which have been stabilized at the same temperature for a minimum of
Route, Transport, Qualification, Profiling, Transport route profiling qualification, Similar
Implementation Working Group ICH Q11 Guideline ...
database.ich.orgmeaning that the proposed starting material should be structurally similar to the drug substance. However, as stated in ICH Q11, this general principle is intended to help distinguish starting materials from reagents, catalysts, solvents, or other raw materials.